Premium
Sodium–glucose cotransporter inhibitors and oxidative stress: An update
Author(s) -
Yaribeygi Habib,
Atkin Stephen L.,
Butler Alexandra E.,
Sahebkar Amirhossein
Publication year - 2019
Publication title -
journal of cellular physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.529
H-Index - 174
eISSN - 1097-4652
pISSN - 0021-9541
DOI - 10.1002/jcp.26760
Subject(s) - glycosuria , oxidative stress , diabetes mellitus , medicine , pharmacology , cotransporter , antioxidant , empagliflozin , chemistry , endocrinology , sodium , biochemistry , type 2 diabetes , organic chemistry
Sodium–glucose cotransporter 2 (SGLT2) inhibitors are therapeutic agents that have been used recently to reduce tubular absorption of glucose, leading to enhanced glycosuria, resulting in the reduction of blood glucose and improved diabetes control. Recent data suggest that SGLT2 inhibitors have antioxidant properties that may be key to the reduction in cardiovascular death found in clinical trials. Oxidative stress is involved in the development and progression of atherosclerosis, as well as underlying diabetes complications, and may result from either increased free‐radical production, a reduction in antioxidative capacity, or a combination of both. In this report, we have reviewed the recent evidence of the impact that SGLT2 inhibition may have on improved oxidative stress by either amelioration of free‐radical generation or potentiation of cellular antioxidative capacity, and its importance in the prevention of cardiovascular and diabetes complications.